NCT07380022Completed
Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
The primary objective of the present postdoctoral research is to evaluate the acceptability and adherence of two dietary supplements containing microbial phytase, Goodphyte IB Defense and Goodphyte Immunity, in adult individuals with chronic diseases, namely Idiopathic Inflammatory Bowel Diseases (IIBD)-that is, Crohn's disease (CD) or Ulcerative Colitis (UC)-Arterial Hypertension (AH), Anemia (AN), or Multiple Sclerosis (MS). Secondarily, this study will investigate potential changes in iron and zinc absorption following phytase supplementation in these individuals and, consequently, possible changes in their quality of life.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 21 Dec 2025
- Start date
- 9 Jul 2025
- Primary completion date
- 28 Feb 2026
- Lead sponsor
- University of Thessaly
- NCT number
- NCT07380022
What you commit to
- Study type: Interventional
- Participants enrolled: 100
- From 9 Jul 2025 to the primary completion date, 28 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Renal or hepatic disease
Age
- Inability to provide informed consent (including individuals \<18 years of age)
Other
- Pregnancy or breastfeeding
- Current use of antibiotics or antibiotic use within the past month
- Current use of other probiotic, prebiotic, or synbiotic supplements
- Current use of iron and/or zinc supplements
- Change in the type of therapeutic regimen (pharmacotherapy) within the past three months
- Change in the dosage of the therapeutic regimen (pharmacotherapy) within the past month
- Insufficient understanding of the Greek language
Who the study is looking for
- Crohn's disease: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.
- Ulcerative colitis: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.
- Hypertension: Patients with systolic blood pressure of 130-139 mmHg or diastolic blood pressure of 80-89 mmHg, who maintain blood pressure within these ranges through lifestyle modifications, without active symptoms (e.g., headaches, dizziness), and not receiving antihypertensive medication.
- Anemia: Patients with hemoglobin \<12 g/dL, serum iron \<40 μg/dL, and ferritin \<15 ng/mL for women, and hemoglobin \<13 g/dL, serum iron \<40 μg/dL, and ferritin \<30 ng/mL for men. Absence of severe clinical consequences. Presence of fatigue, weakness, or dizziness, which is usually manageable.
- Multiple sclerosis: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| School of Physical Education, Sport Science and Dietetics Coordinator of this site? Confirm its status | Trikala | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.